The objectives of this ePoster was to assess United States laboratory real-world NGS testing rates based on public and commercial claims data and the lab readiness of key US labs based on their offering of comprehensive genomic testing and coverage of established and emerging rare mutations of mNSCLC.
IASLC ePoster:Real-world readiness of US laboratories to test metastatic NSCLC patients for rare actionable genomic variants by NGS
Various rare driver mutations have been studied in non-squamous Non-small Cell Lung Cancer (NSCLC). Individually they are considered rare (<3% prevalence), however, collectively they can represent up to 15.1% of the NSCLC mutation profile. Therapies targeting rare mutations in NSCLC such as ROS1, NTRK, RET, have been approved to be used at 1st line for metastatic NSCLC (mNSCLC). With many more therapies under development, there is an increased need to use multi-gene testing such as NGS to ensure that all relevant actionable variants are tested prior to 1st line treatment.